Barclays Maintains Equal-Weight on Doximity, Raises Price Target to $27
Barclays analyst Glen Santangelo maintains Doximity (NYSE:DOCS) with a Equal-Weight and raises the price target from $20 to $27.
Read original at benzingaStocks · News reference
Doximity Announces Doximity Ask Came Ahead Of Frontier AI Models In Numerous Options Harm Assessment For Risk In Medicine Benchmark
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that Doximity Ask, its HIPAA-compliant clinical AI platform, outperformed leading frontier AI models in the NOHARM
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 6:27 PM
- Checked
- Jul 15, 2026, 6:27 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
What Investors Should Know of This Doximity Officer's Latest Insider Transaction
Doximity's Chief Accounting Officer Siddharth Sitaram sold 5,652 shares worth $140,400 in mid-August. The transaction was driven by routine tax obligations from option exercises and restricted stock unit vesting rather than a loss of confidence in the company. Sitaram retains significant equity holdings of 93,122 shares. The sale reflects standard tax-driven liquidity management common among executives.
Read original at the-motley-foolDoximity Handed Its President 150,000 Options Last Month. Here's What the Latest Filing Signals for Investors
Doximity's president Steven Zatz sold 4,482 shares worth $111,154 on August 15 through a routine tax withholding transaction upon restricted stock unit vesting. Zatz retains 51,864 directly held shares valued at $1.29 million, but his significant upside exposure comes from 150,000 options granted in July with a $20.49 strike price that don't vest until July 2027. The timing is notable given Doximity's recent earnings showed 7% revenue growth but margin compression due to higher-than-expected AI compute costs, with the CFO characterizing this as a 'good problem' as AI search revenue recognition is expected in Q3.
Read original at the-motley-foolDoximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know.
Doximity's new CFO Matthew Sonefeldt sold 15,311 shares worth $380,000 in a non-discretionary transaction tied to restricted stock unit vesting and tax obligations. The sale reduced his holdings by only 3%, leaving him with a $12.1 million equity stake. The filing comes as the company faces slowing growth with Q3 guidance at only 1% growth midpoint, tight pharma spending, and margin pressure from AI compute costs, though management expects improvement in Q3 when AI search revenue lands.
Read original at the-motley-fool